Compare OGN & WLFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | WLFC |
|---|---|---|
| Founded | 1923 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2020 | 1997 |
| Metric | OGN | WLFC |
|---|---|---|
| Price | $13.38 | $179.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $11.40 | ★ $160.00 |
| AVG Volume (30 Days) | ★ 5.0M | 93.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | 0.60% | ★ 0.86% |
| EPS Growth | N/A | ★ 146.23 |
| EPS | 0.55 | ★ 3.26 |
| Revenue | ★ $6,216,000,000.00 | $569,223,000.00 |
| Revenue This Year | $0.45 | $2.75 |
| Revenue Next Year | $1.67 | $7.35 |
| P/E Ratio | ★ $24.28 | $56.21 |
| Revenue Growth | N/A | ★ 36.00 |
| 52 Week Low | $5.69 | $114.01 |
| 52 Week High | $13.48 | $239.44 |
| Indicator | OGN | WLFC |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 40.36 |
| Support Level | $10.05 | $175.13 |
| Resistance Level | $13.46 | $185.85 |
| Average True Range (ATR) | 0.05 | 8.14 |
| MACD | -0.22 | -2.25 |
| Stochastic Oscillator | 47.50 | 11.17 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.